Roivant Sciences Financing Cash Flow increased by 274.8% to $328.19M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 220.2%, from -$272.95M to $328.19M. Over 3 years (FY 2021 to FY 2024), Financing Cash Flow shows a downward trend with a 57.0% CAGR.
Negative values often indicate a company is paying down debt or returning capital to shareholders, while positive values may indicate external financing.
The net result of all cash inflows and outflows related to financing activities, including debt issuance, debt repayment...
Highly dependent on the company's current capital structure and lifecycle stage compared to industry peers.
net_cash_from_financing| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $10.21M | $303.93M | $0.00 | $1.07M | $141.98M | $0.00 | $154.50M | $210.33M | $7.48M | $207.87M | $236.64M | $0.00 | -$660.62M | -$109.07M | -$272.95M | -$177.15M | -$187.77M | $328.19M |
| QoQ Change | — | >999% | -100.0% | — | >999% | -100.0% | — | +36.1% | -96.4% | >999% | +13.8% | -100.0% | — | +83.5% | -150.2% | +35.1% | -6.0% | +274.8% |
| YoY Change | — | — | — | — | >999% | -100.0% | — | >999% | -94.7% | — | +53.2% | -100.0% | <-999% | -152.5% | -215.3% | — | +71.6% | +220.2% |